Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Top Cited Papers
- 14 November 2019
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 394 (10214), 2096-2107
- https://doi.org/10.1016/s0140-6736(19)32556-5
Abstract
No abstract availableKeywords
Funding Information
- Sanofi Pasteur
This publication has 29 references indexed in Scilit:
- Monoclonal antibodies targeting CD38 in hematological malignancies and beyondImmunological Reviews, 2016
- SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomideLeukemia, 2015
- SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic MalignanciesClinical Cancer Research, 2014
- Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 studyBlood, 2014
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trialThe Lancet Oncology, 2013
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group studyLeukemia, 2011
- International uniform response criteria for multiple myelomaLeukemia, 2006
- Flow Cytometric Immunophenotypic Analysis of 306 Cases of Multiple MyelomaAmerican Journal of Clinical Pathology, 2004
- Development of an EORTC questionnaire module to be used in health‐related quality‐of‐life assessment for patients with multiple myelomaBritish Journal of Haematology, 1999
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1993